Except possibly for hypertensive patients, screening for type 2 diabetes provides few benefits, according to a report in the June 3rd Annals of Internal Medicine. Accordingly, revised guidelines from the U.S. Preventive Services Task Force (USPSTF) recommend screening only for adults with sustained blood pressure above 135/80 mm Hg. See Publishers …

Further evidence that vitamin-D deficiency may increase the risk of heart disease has come from a new case-control study.

I had the unique pleasure of attending a couple of investor meetings with Dave Kliff our good friend at Diabetic Investor and that was an awakening in itself. At those meetings it is all about the money, and Dave has prepared an overview of the GLP-1 game. Click here to …

A1C Translation to Estimated Average Glucose (eAG) Units Will Yield Easier Patient Education. New more accurate formula used to convert A1c to average blood glucose.

The world’s largest diabetes trial has shown intensive blood glucose can reduce the risk of kidney disease by 21% with no evidence of any increased risk of death when blood glucose was intensively controlled.

A major 7.5 year long-term U.S. clinical trial to study whether intense control of blood glucose in type 2 diabetes would reduce the risk of cardiovascular disease found a reduction in cardiovascular events, but it was not statistically significant, according to a report presented at the American Diabetes Association’s 68th Annual …

For the first time a previously unrecognized harm due to a strategy of intensified glucose lowering in high risk patients with type 2 diabetes has been identified, according to a report at the American Diabetes Association’s 68th Annual Scientific Sessions.

Favorable 5-Year Outcome for Asymptomatic People with Type 2 Without Evidence of Coronary Artery Disease. Expensive Screening Not Needed When Standard Clinical Care and Follow-Up Attentive

New studies show GlycoMark may be a more effective monitor than A1c of exenatide, sitagliptin, pramlintide and prandaial insulin thereapies in certain diabetic populations.

InteKrin Therapeutics Presented Phase 2a Data INT131, a non-TZD SPPARM